Skip to content. | Skip to navigation

Personal tools
Log in


You are here: Home / About / Publication Announcements / H2AFX and Non-Hodgkin Lymphoma

H2AFX and Non-Hodgkin Lymphoma

Genetic variation in H2AFX contributes to risk of non-Hodgkin lymphoma.
Scientists at Canada's Michael Smith Genome Sciences Centre and their collaborators at the BC Cancer Agency have discovered that genetic variation in the H2AFX gene influences susceptibility to some subtypes of Non-Hodgkin lymphoma (NHL) by contributing to the maintenance of genome stability.  NHL is a group of solid tumors of lymphoid origin and the seventh most commonly diagnosed cancer worldwide.  H2AFX is fundamental to the detection of, and response to, breaks in the DNA of all cells.  These breaks need to be repaired promptly, or the cell needs to be destroyed, to prevent mutations occuring and perpetuating which can ultimately lead to malignancy.

Full citation

Novik KL,
Spinelli JJ, Macarthur AC, Shumansky K, Sipahimalani P, Leach S, Lai A, Connors JM, Gascoyne RD, Gallagher RP, Brooks-Wilson AR.  Genetic variation in H2AFX contributes to risk of non-Hodgkin lymphoma.  Cancer Epidemiol Biomarkers Prev. 2007 Jun;16:1098-1106.

Further details of this publication can be found online at:

Page last modified Sep 18, 2008